Intellia Therapeutics Inc (NTLA) concluded trading on Thursday at a closing price of $8.28, with 5.37 million shares of worth about $44.45 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -45.31% during that period and on May 08, 2025 the price saw a gain of about 13.58%. Currently the company’s common shares owned by public are about 102.03M shares, out of which, 97.49M shares are available for trading.
Stock saw a price change of -4.17% in past 5 days and over the past one month there was a price change of 31.85%. Year-to-date (YTD), NTLA shares are showing a performance of -28.99% which decreased to -65.09% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.90 but also hit the highest price of $28.18 during that period. The average intraday trading volume for Intellia Therapeutics Inc shares is 3.50 million. The stock is currently trading 4.66% above its 20-day simple moving average (SMA20), while that difference is down -0.76% for SMA50 and it goes to -43.28% lower than SMA200.
Intellia Therapeutics Inc (NASDAQ: NTLA) currently have 102.03M outstanding shares and institutions hold larger chunk of about 89.82% of that.
The stock has a current market capitalization of $857.67M and its 3Y-monthly beta is at 2.28. It has posted earnings per share of -$5.25 in the same period. It has Quick Ratio of 5.77 while making debt-to-equity ratio of 0.24. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NTLA, volatility over the week remained 9.43% while standing at 9.04% over the month.
Stock’s fiscal year EPS is expected to rise by 15.04% while it is estimated to increase by 5.26% in next year. EPS is likely to grow at an annualized rate of 22.77% for next 5-years, compared to annual growth of -20.04% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wolfe Research on April 21, 2025 offering an Outperform rating for the stock and assigned a target price of $21 to it. Coverage by H.C. Wainwright stated Intellia Therapeutics Inc (NTLA) stock as a Buy in their note to investors on March 05, 2025, suggesting a price target of $30 for the stock. On February 28, 2025, JP Morgan Downgrade their recommendations, while on February 28, 2025, Goldman Downgrade their ratings for the stock with a price target of $9. Stock get an Equal-weight rating from Morgan Stanley on January 27, 2025.
